![cover image](https://wikiwandv2-19431.kxcdn.com/_next/image?url=https://upload.wikimedia.org/wikipedia/commons/thumb/8/88/Captodiame.svg/640px-Captodiame.svg.png&w=640&q=50)
Captodiame
Chemical compound / From Wikipedia, the free encyclopedia
Captodiame (INN), also known as captodiamine, is an antihistamine sold under the trade names Covatine, Covatix, and Suvren which is used as a sedative and anxiolytic. The structure is related to diphenhydramine.[2]
![]() | |
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Excretion | Renal |
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG |
|
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.006.936 ![]() |
Chemical and physical data | |
Formula | C21H29NS2 |
Molar mass | 359.59 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
A 2004 study suggested captodiame may be helpful in preventing benzodiazepine withdrawal syndrome in people discontinuing benzodiazepine treatment.[2]
In addition to its actions as an antihistamine, captodiamine has been found to act as a 5-HT2C receptor antagonist and σ1 receptor and D3 receptor agonist.[3] It produces antidepressant-like effects in rats.[3] However, captodiamine is unique among antidepressant-like drugs in that it increases brain-derived neurotrophic factor (BDNF) levels in the hypothalamus but not in the frontal cortex or hippocampus.[3] This unique action may be related to its ability to attenuate stress-induced anhedonia and corticotropin-releasing factor (CRF) signaling in the hypothalamus.[3]